Delcath announces inducement grant under nasdaq listing rule 5635(c)(4)

Queensbury, n.y.--(business wire)--delcath systems, inc. (nasdaq: dcth) (the “company” or “delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the company granted an equity award, previously approved by the company's compensation committee, as a material inducement to the employment of an individual whose employment commenced on november 4, 2024. the grant totaled the right to purchase 30,000 shares of the company.
NDAQ Ratings Summary
NDAQ Quant Ranking